Kala Pharmaceuticals Gears Up for IPO
Kala Pharmaceuticals intends to price 6 million shares in the range of $14 to $16 apiece in an initial public offering valued up to more than $110 million.
All Work
Chris Lange
JPMorgan, Wells Fargo and More Kicking Off Earnings Season This Week
The main companies reporting this week are banks, which always kick off the earnings season. Although only three major banks are reporting this week, the rest will be coming along very shortly.
Looking Under the Hood of the Auto Parts Industry Crash
This past week was absolutely catastrophic for the retail auto parts industry. It all kicked off when O’Reilly Automotive provided an update ahead of its second-quarter financial results. But O’Reilly wasn’t the only one…
FDA Issues an Approval Not Seen in Almost 20 Years
In an incredible move on Friday, the FDA approved Endari for the treatment of patients age five and older with sickle cell disease to reduce severe complications that are common with the blood disorder.
Is It Time to Start Buying Cliffs?
Cliffs Natural Resources always has offered a high leverage to U.S. steel prices, and over the past seven years this hasn’t been a positive for investors. However one analyst seems to think that there’s…
Will Campbell Soup Finally Win in Organics With This Acquisition?
In the past, Campbell has tried to move into organic foods but was not entirely successful, so the question is whether it can hit the mark on this latest acquisition.
Why Conatus Pharma Wins With Newest Licensing Agreement
Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was an absolutely catastrophic day for the broad markets with practically everything sinking. There were a few stocks that held out and didn’t lose on the day but those were few and far…
Why Investors Are Stripping L Brands Down
L Brands saw its shares take a dip on Thursday after the company gave an update on its most recent month of sales. Unfortunately results did not live up to expectations and investors stripped…
What Analysts Are Saying About Auto Parts Retailers After Wednesday’s Carnage
The auto parts retailer industry took a big hit on Wednesday after O’Reilly Automotive provided an update ahead of its second-quarter financial results.
Is Mazor Robotics Really on Track for Its Best Quarter Ever?
Mazor Robotics saw its shares make a handy gain on Thursday after the Israeli firm announced that it’s projecting to report record revenues for the second quarter.
How Transformative Is This Licensing Deal for BeiGene?
This partnership should be fairly transformative for BeiGene, seeing as it can start making some actual money.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a relatively stable day for the markets with all the major U.S. indices posting a gain on the day. Despite this, crude oil veered sharply negative on the day after Russia announced…
How One Bolt-On Merger Can Help AK Steel Transform
AK Steel has sold off just a bit after the steel giant recently announced that it will acquire Precision Partners for a total of $360 million in cash.
Athenex Wins Big on Chinese Cancer Drug
Athenex led biotech stocks higher on Wednesday after its Chinese subsidiary submitted an Investigational New Drug application to the China Food and Drug Administration.
Is Amazon Dismantling the Auto Parts Industry?
O’Reilly Automotive was under fire early Wednesday after the auto parts retailer announced its same-store sales numbers ahead of its earnings report. This news could be indicative of the industry as a whole.
Array BioPharma’s New FDA Submissions Enough to Excite Investors?
Array BioPharma has announced the submission to the FDA of two New Drug Applications to support the use of the combination of binimetinib and encorafenib for the treatment of patients with melanoma.
Why Analysts Ganged Up on Nike After Earnings
Management believes that Nike is poised for a big year, but there seem to be mixed feelings in the analyst community. Some analysts are coming to defend the Swoosh while others think apparel trends…
The 11 Biggest and Best Analyst Upgrades of June
While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it is important to understand that there is a much larger risk when an analyst…
Top Stocks to Look For on July’s FDA Calendar
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of July and added some color.